Perfluoroalkyl Acids in Drinking Water – EPA Method 537

Jul 26, 2016 | Blogs, Environmental / Industrial | 0 comments

The United States Environmental Protection Agency (EPA), under the 1996 Safe Drinking Water Act (SDWA), requires a new list of no more than 30 unregulated contaminants to be monitored by public drinking water systems. Known as the Unregulated Contaminant Monitoring Rule (UCMR), a new list is published every five years. The last rule, UCMR3, was published May 2, 2012, and is the focus of the following application note, “Analysis of Perfluoroalkyl (PFFA) Acids Specified under the UCMR3 Using the QTRAP® 6500 LC-MS/MS system,” which can be found in the Food and Environmental Compendium.

Overview
Using the guidelines laid out by EPA Method 537, “A Determination of Selected Perfluoroalkyl Acids in Drinking Water by Solid Phase Extraction and Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS),” this application note describes the performance of the QTRAP 6500. Within the scope of EPA 537, there are 14 PFAAs. Six are specified under the UCMR3 monitoring list.

Process
Sample preparation and data processing were carried out according to EPA Method 537 without deviation unless specifically noted. The analysis was carried out using the QTRAP 6500 coupled with the Agilent 1260 HPLC with an Eksigent ULC 100 HTC-xt autosampler. Quantitation using MultiQuant ™ 3.0.

Conclusion
The lower the detection, the harder the QTRAP 6500 works for you as it easily meets the UCMR3 reporting limits. See what more it can do when you download the compendium. Download the compendium >

How SCIEX Now empowers mass spec users to work with more control, clarity and confidence

In this interview, Andy Wilcox, Senior Market Development Manager, Aftermarket and Software, speaks with Susanna Baqué, Senior Director of Global Customer Experience, about how SCIEX Now gives customers one connected digital workspace to manage instruments, reduce time spent searching for information, resolve issues faster and keep their laboratory running more efficiently and with greater confidence.

Bioanalysis across modalities: Advancing confident decisions with modern LC‑MS strategies

As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.

The rules have changed

Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.

Posted by

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network